Zadnji put ažurirano :
19/11/2024
Inhibitori protonske pumpe   Esomeprazole sodium  
injekcija
Stabilizacija rješenja Stabilnost mješavine Stabilizacijski faktor Kompatibilnosti način davanja lijeka Bibliografija pdf
   Kemijska struktura  

Nekomercijalni   Nekomercijalni     

Zaštićeni nazivi su indikativni i sastav ekscipijensa može biti različit ovisno o državi i laboratorijima

Adptor Meksiko
Axagon Italija
Axiago Švedska
Cativa Švedska
Cronopep Kolumbija, Peru
Eliprot Ekvador
Emune Ekvador
Epral Čile
Esio Ekvador
Esmonat Indija, Turska
Esoblok Turska
Esofax Ekvador
Esolium Peru
Esomep Švicarska
Esomeprazol Čile, Ekvador, Kolumbija, Rumunjska, Španjolska
Esomeprazole S A D
Esopral Italija, Švedska
Esopran Peru
Esoton Plus Peru
Esoz Indija, Kolumbija
Ezole Peru
Gletop Venecuela
Inexium Francuska
Milenium Ekvador
Nexiam Belgija, Luksemburg
Nexium Argentina, Čile, Egipat, Ekvador, Grčka, Irska, Island, Italija, Kolumbija, Malezija, Meksiko, Njemačka, Norveška, Portugal, Rumunjska, S A D, Saudijska Arabija, Španjolska, Švedska, Švicarska, Turska, Ujedinjeni Arapski Emirati, Velika Britanija, Venecuela
Redica Švedska
Refexxin Švedska
Bibliografija   injekcija   Bibliografija : Esomeprazole sodium  
Vrsta Publikacija
1506 Časopis Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D.
Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units.
EJHP 2015 ;22:107-112.
1508 Časopis Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
2262 Časopis Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Časopis Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2270 Časopis Kupiec TC, Aloumanis V, Ben M, Trissel LA, Chan P, Patterson J.
Physical and chemical stability of esomeprazole sodium solutions.
Ann Pharmacotherapy 2008 ; 42, 9: 1247-1251.
2284 Laboratorija Esomeprazole sodium (Nexium IV®) – Summary of Product Characteristics
Astra Zenaca 2007
2311 Časopis Kambia N.K, Luyckx M, Dine T, Dupin-Spriet T, Gressier B, Brunet C.
Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
J Clin Pharm Ther 2009 ; 34: 25-31.
3249 Časopis Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254 Časopis Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332 Laboratorija Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012
3372 Časopis Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3429 Časopis Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S.
Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration
Am J Health-Syst Pharm 2015 ; 72:483-486
3827 Plakat Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Plakat Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Plakat So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3879 Časopis Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E.
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3948 Časopis Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
4055 Časopis Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Časopis Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4433 Časopis Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4465 Časopis Foushee A, Meredith P, Fox Laura, Wilder A.
Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients.
Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4528 Časopis Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4650 Laboratorija Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4801 Časopis Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:

  Mentions Légales